191 related articles for article (PubMed ID: 25843293)
21. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
22. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
23. Positive auto-regulation of MYCN in human neuroblastoma.
Suenaga Y; Kaneko Y; Matsumoto D; Hossain MS; Ozaki T; Nakagawara A
Biochem Biophys Res Commun; 2009 Dec; 390(1):21-6. PubMed ID: 19766596
[TBL] [Abstract][Full Text] [Related]
24. Cell cycle regulation targets of MYCN identified by gene expression microarrays.
Bell E; Lunec J; Tweddle DA
Cell Cycle; 2007 May; 6(10):1249-56. PubMed ID: 17495526
[TBL] [Abstract][Full Text] [Related]
25. p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.
Horvilleur E; Bauer M; Goldschneider D; Mergui X; de la Motte A; Bénard J; Douc-Rasy S; Cappellen D
Nucleic Acids Res; 2008 Aug; 36(13):4222-32. PubMed ID: 18583365
[TBL] [Abstract][Full Text] [Related]
26. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.
Gualdrini F; Corvetta D; Cantilena S; Chayka O; Tanno B; Raschellà G; Sala A
Oncotarget; 2010 Aug; 1(4):278-288. PubMed ID: 21304178
[TBL] [Abstract][Full Text] [Related]
27. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
28. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
29. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.
Buechner J; Tømte E; Haug BH; Henriksen JR; Løkke C; Flægstad T; Einvik C
Br J Cancer; 2011 Jul; 105(2):296-303. PubMed ID: 21654684
[TBL] [Abstract][Full Text] [Related]
30. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.
Bell E; Premkumar R; Carr J; Lu X; Lovat PE; Kees UR; Lunec J; Tweddle DA
Cell Cycle; 2006 Nov; 5(22):2639-47. PubMed ID: 17172827
[TBL] [Abstract][Full Text] [Related]
31. SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.
Bretones G; Acosta JC; Caraballo JM; Ferrándiz N; Gómez-Casares MT; Albajar M; Blanco R; Ruiz P; Hung WC; Albero MP; Perez-Roger I; León J
J Biol Chem; 2011 Mar; 286(11):9815-25. PubMed ID: 21245140
[TBL] [Abstract][Full Text] [Related]
32. Suppression of centrosome amplification after DNA damage depends on p27 accumulation.
Sugihara E; Kanai M; Saito S; Nitta T; Toyoshima H; Nakayama K; Nakayama KI; Fukasawa K; Schwab M; Saya H; Miwa M
Cancer Res; 2006 Apr; 66(8):4020-9. PubMed ID: 16618721
[TBL] [Abstract][Full Text] [Related]
33. Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
Murphy DM; Buckley PG; Das S; Watters KM; Bryan K; Stallings RL
PLoS One; 2011; 6(6):e21436. PubMed ID: 21731748
[TBL] [Abstract][Full Text] [Related]
34. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
[TBL] [Abstract][Full Text] [Related]
35. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.
Woo CW; Tan F; Cassano H; Lee J; Lee KC; Thiele CJ
Pediatr Blood Cancer; 2008 Feb; 50(2):208-12. PubMed ID: 17420990
[TBL] [Abstract][Full Text] [Related]
36. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
[TBL] [Abstract][Full Text] [Related]
37. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells.
Gu L; Zhang H; He J; Li J; Huang M; Zhou M
Oncogene; 2012 Mar; 31(11):1342-53. PubMed ID: 21822304
[TBL] [Abstract][Full Text] [Related]
38. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
[TBL] [Abstract][Full Text] [Related]
39. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
40. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
